Study Supports Early Anticoagulant Treatment to Reduce Death in Moderately Ill COVID-19 Patients

Findings from an international multicenter trials showed that while a full dose of heparin didn’t statistically significantly lower incidence of the primary composite of death, mechanical ventilation or ICU admission compared with low-dose heparin, therapeutic heparin did reduce the odds of all-cause death by 78 percent.

Genetic testing proves beneficial in prescribing effective blood thinners

A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care providers choose the appropriate anti-platelet drug. Testing helps determine if a patient carries genetic variants in CYP2C19 that cause loss of its function. These variants interfere with the body’s ability to metabolize and activate clopidogrel, an anti-platelet medication.

Benefits of High-dose Blood Thinners in COVID-19 Patients Remain Unclear

While COVID-19 infected patients should be treated with standard anticoagulation therapies, such as blood thinning medication, a new study by researchers at the George Washington University shows that anticoagulating patients at higher doses, without traditional medical indications to do so, may be ineffective and even harmful. 

Morristown Medical Center’s Dr. Stephen Winters Discusses What Everyone Should Know About Atrial Fibrillation

September is National Atrial Fibrillation Month, and Stephen L. Winters, MD, director of the Cardiac Rhythm Management Program, Gagnon Cardiovascular Institute, Atlantic Health System’s Morristown Medical Center, wants the public to know some surprising facts about this increasingly common heart condition.

Mount Sinai Study Finds COVID-19 May Be Driven by Pulmonary Thrombi and Pulmonary Endothelial Dysfunction

A new study from the Icahn School of Medicine at Mount Sinai suggests that blood clots, especially in the lungs, may play a role in severe cases of COVID-19.

Treating Pulmonary Embolism: How Safe and Effective Are New Devices?

A new scientific statement from the American Heart Association identifies the risks and benefits of using novel interventional devices compared to anticoagulation alone to treat patients with pulmonary embolism.